Clinical Trial

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Study acronym: EPACRA-AKI
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-18; most recent amendment 2025-11-18.
Status change: Recruiting → Active, Not Recruiting 2025-11-18
Status change: Not Yet Recruiting → Recruiting 2024-11-01
Trial Details
NCT Number NCT06652100
Lead Sponsor BioPorto Diagnostics
Collaborators: ProPharma Group
Conditions Acute Kidney Injury
Enrollment 800 participants
Start Date 2024-10-28
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-19